Will P. J. M. Spooren
CNS Disease Biology Area
pRED, Building 74/3W308
Basel CH-4070
Switzerland
Name/email consistency: high
- Metabotropic glutamate receptors: their therapeutic potential in anxiety. Spooren, W., Lesage, A., Lavreysen, H., Gasparini, F., Steckler, T. Curr. Top. Behav. Neurosci (2010)
- Opinion: NK3 receptor antagonists: the next generation of antipsychotics?. Spooren, W., Riemer, C., Meltzer, H. Nat. Rev. Drug. Discov (2005)
- Pharmacological and genetic evidence indicates that combined inhibition of NR2A and NR2B subunit containing NMDA receptors is required to disrupt prepulse inhibition. Spooren, W., Mombereau, C., Maco, M., Gill, R., Kemp, J.A., Ozmen, L., Nakanishi, S., Higgins, G.A. Psychopharmacology (Berl.) (2004)
- mGlu5 receptor antagonists: a novel class of anxiolytics?. Spooren, W., Gasparini, F. Drug News Perspect. (2004)
- Insight into the function of Group I and Group II metabotropic glutamate (mGlu) receptors: behavioural characterization and implications for the treatment of CNS disorders. Spooren, W., Ballard, T., Gasparini, F., Amalric, M., Mutel, V., Schreiber, R. Behav. Pharmacol (2003)
- Pharmacological and endocrinological characterisation of stress-induced hyperthermia in singly housed mice using classical and candidate anxiolytics (LY314582, MPEP and NKP608). Spooren, W.P., Schoeffter, P., Gasparini, F., Kuhn, R., Gentsch, C. Eur. J. Pharmacol. (2002)
